PeptiDream Inc. (TYO:4587)
Japan · Delayed Price · Currency is JPY | Market Cap | 125.01B -43.1% |
| Revenue (ttm) | 19.05B -59.2% |
| Net Income | -3.57B |
| EPS | -27.64 |
| Shares Out | 128.49M |
| PE Ratio | n/a |
| Forward PE | 9.89 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 334,100 |
| Open | 981.30 |
| Previous Close | 972.90 |
| Day's Range | 977.80 - 999.70 |
| 52-Week Range | 916.00 - 1,818.50 |
| Beta | 0.15 |
| Analysts | Buy |
| Price Target | 2,825.00 (+183.41%) |
| Earnings Date | Aug 12, 2026 |
About PeptiDream
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug discovery platform that integrates the technologies to synthesize highly diverse macrocyclic peptide libraries and screen for hit compounds, as well as enables rapid and efficient identification of novel hit compounds with high potency and selectivity for protein targets in drug discovery c... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for 4587 stock is "Buy." The 12-month stock price target is ¥2,825, which is an increase of 183.41% from the latest price.
News
PeptiDream Announces First Dosing of Claudin18.2 Targeting Radiopharmaceutical Candidate 64Cu-PD-29875 in Patients with Gastric Cancer
KAWASAKI, Japan--(BUSINESS WIRE)-- #DrugDelivery--The first patient has been dosed with 64Cu-PD-29875 in a first-in-human clinical study in patients with gastric cancer.
PeptiDream, PDRadiopharma and Curium Group Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
KAWASAKI, Japan--(BUSINESS WIRE)-- #Cancer--Completion of patient dosing in the registrational Phase 2 clinical trial of 64Cu-PSMA-I&T —a PET radiopharmaceutical targeting PSMA.
Curium Group, PeptiDream and PDRadiopharma Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
BOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Curium Group announced today that together with PeptiDream Inc. and PDRadiopharma Inc., patient dosing has been completed in the registrational Phase 2 clinic...
PeptiDream Transcript: Jefferies Global Healthcare Conference 2026
The company is rapidly expanding its clinical pipeline, especially in radiopharmaceuticals and oral peptide therapeutics, while advancing new modalities and leveraging AI for efficiency. Organizational changes and strategic in-licensing support growth, with a focus on reinvesting profits to drive clinical development and maximize value.
PeptiDream Quarterly report: Q1 2026
PeptiDream has published its Q1 2026 quarterly earnings report on May 13, 2026.
PeptiDream announces initiation of Phase 1 clinical trial of AK1940
PeptiDream (PPTDF) announced that Asahi Kasei Therapeutics (AHKSY), its collaboration partner, has initiated a Phase 1 clinical trial of “AK1940”, a selective inhibitor of TNF receptor 1. AK1940 is a…
PeptiDream Announces the Initiation of Phase 1 Clinical Trial by Its Collaboration Partner
KAWASAKI, Japan--(BUSINESS WIRE)-- #AutoimmuneDisease--PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter “PeptiDream”) today announced ...
PeptiDream downgraded to Neutral from Buy at Citi
Citi downgraded PeptiDream (PPTDF) to Neutral from Buy with a price target of 1,600 yen, down from 2,700 yen. The firm says the company’s product out-licensing is taking longer than…
PeptiDream Earnings Call Transcript: Q4 2025
2025 saw nearly double the clinical programs and strong radiopharmaceutical growth, though revenue missed forecasts due to delayed out-licensing. FY2026 guidance is conservative, with 6–12 new clinical programs expected and increased R&D investment, aiming for long-term revenue growth and pipeline expansion.
PeptiDream Quarterly report: Q4 2025
PeptiDream has published its Q4 2025 quarterly earnings report on February 16, 2026.
PeptiDream Slides: Q4 2025
PeptiDream has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 16, 2026.
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan
BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Curium Group today announced that together with PeptiDream Inc. and PDRadiopharma Inc., the first patient has been dosed in the companies' registrational clin...
PeptiDream Announces Promising Pre-Clinical Results of Proprietary Oral IL-17A and IL-17F Dual Inhibitor with Biologic-Like Efficacy for the Treatment of Psoriasis
KAWASAKI, Japan--(BUSINESS WIRE)-- #IL17--PeptiDream is advancing the oral IL-17a/ IL-17F dual inhibitor peptide program into IND-enabling studies, while exploring strategic partnerships.
PeptiDream Transcript: Status Update
Significant R&D progress was made across radiopharmaceuticals and peptide therapeutics, with multiple programs advancing to clinical stages and robust growth in the radiopharmaceutical business. Major capital investments are underway to expand R&D and manufacturing capacity, supporting a strong outlook for continued pipeline expansion and innovation.
PeptiDream Slides: Status Update
PeptiDream has posted slides in relation to its latest quarterly earnings report, which was published on December 5, 2025.
PeptiDream Quarterly report: Q3 2025
PeptiDream has published its Q3 2025 quarterly earnings report on November 12, 2025.
PeptiDream Quarterly report: Q2 2025
PeptiDream has published its Q2 2025 quarterly earnings report on August 8, 2025.
PeptiDream Slides: Q2 2025
PeptiDream has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 8, 2025.
PeptiDream Quarterly report: Q1 2025
PeptiDream has published its Q1 2025 quarterly earnings report on May 13, 2025.
PeptiDream Earnings Call Transcript: Q4 2024
Record FY2024 results with revenue up 163% and net income up nearly 500% year-over-year, driven by expanded partnerships and pipeline progress. FY2025 guidance is conservative, with upside potential from major out-licensing deals and continued pipeline expansion.
PeptiDream Quarterly report: Q4 2024
PeptiDream has published its Q4 2024 quarterly earnings report on February 13, 2025.
PeptiDream Slides: Q4 2024
PeptiDream has posted slides in relation to its Q4 2024 quarterly earnings report, which was published on February 13, 2025.
PeptiDream Transcript: Investor Day 2024
The company is rapidly expanding its radiopharmaceutical and peptide therapeutic pipelines, launching new internal programs and advancing multiple partnered assets into clinical stages. Platform innovations in automation and AI are accelerating discovery and optimization, supporting a goal of at least one new internal program annually.
PeptiDream Slides: FY 2024
PeptiDream has posted slides in relation to its FY 2024 quarterly earnings report, which was published on December 11, 2024.
PeptiDream Quarterly report: Q3 2024
PeptiDream has published its Q3 2024 quarterly earnings report on November 13, 2024.